Therapeutic news in ALS

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by death of motor neurons in the cortex and spinal cord. This loss causes progressive weakness amyotrophy. To date, median duration survival patients with ALS, from first symptoms to death, estimated be 36 months. Currently treatment limited two options: riluzole which prolongs for few months edaravone available only countries also has small impact on progression. There an urgent need more effective drugs this significantly improve Over last 30 years, all trials have failed find curative drug ALS. due, partially, heterogeneity clinical features pathophysiology neuron death. We present review various options currently being developed emphasis range therapeutic approaches explored, old tested new indication innovative obtained via biotechnology or gene therapy.